- Home
- GLQ vs HBIO Comparison
GLQ vs HBIO Comparison
Compare GLQ & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLQ | HBIO |
|---|---|---|
| Founded | 2005 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 33.8M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GLQ | HBIO |
|---|---|---|
| Price | $7.66 | $0.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 65.5K | ★ 864.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 11.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $87,371,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.13 | $0.28 |
| 52 Week High | $6.54 | $2.28 |
Technical Indicators
Market Signals| Indicator | GLQ | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 57.45 |
| Support Level | $7.40 | $0.74 |
| Resistance Level | $7.74 | $0.84 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 66.67 | 46.43 |
Price Performance
Historical ComparisonAbout GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.